文献速递膀胱癌与上尿路尿路上皮癌

肿瘤微环境的空间关系与肌层浸润性膀胱癌新辅助化疗免疫治疗的病理缓解相关

Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer.
PubMed 文献 · Eur Urol · 2023-12-12

对来自两项新辅助化疗(吉西他滨联合顺铂)联合免疫检查点抑制剂研究(LCCC1520[帕博利珠单抗]和BLASST-1[纳武利尤单抗])的18例缓解者(<ypT2)和18例未缓解者(≥ypT2)的经尿道膀胱肿瘤切除标本,用NanoString GeoMx平台进行蛋白组数字空间 profiling(DSP)。结果显示DSP标记表达瘤内异质性高,但病理缓解与特定DSP标记在空间依赖背景下相关;包含兴趣区域标记的弹性网模型验证集表现(AUC=0.827)优于忽略兴趣区域的模型(AUC=0.432)。

要点

  • DSP标记表达瘤内异质性高,但缓解与PD-L1(不区分兴趣区域)、Ki-67(不区分兴趣区域、肿瘤富集区、免疫富集区及肿瘤界面)、HLA-DR(肿瘤界面)和HER2(肿瘤富集区)等标记相关。
  • 包含兴趣区域标记的弹性网模型验证集AUC为0.827,优于忽略兴趣区域模型的AUC 0.432。
  • 包含DSP、肿瘤突变负荷和临床数据的模型表现(AUC=0.821)不优于仅DSP模型。

核心结论

  • 尽管基于DSP的标记表达存在高度瘤内异质性,我们观察到病理缓解与特定DSP标记在空间依赖背景下存在关联。
  • 进一步探索肿瘤区域特异性生物标志物可能有助于预测肌层浸润性膀胱癌对新辅助化疗免疫治疗的缓解。

研究设计与样本

  • 对来自两项新辅助化疗(吉西他滨联合顺铂)联合免疫检查点抑制剂研究(LCCC1520[帕博利珠单抗]和BLASST-1[纳武利尤单抗])的18例缓解者(<ypT2)和18例未缓解者(≥ypT2)的经尿道膀胱肿瘤切除标本进行蛋白组数字空间 profiling(DSP)。
  • 预处理肿瘤样本经苏木精-伊红和免疫荧光(panCK和CD45)染色以选择四个兴趣区域(ROI):肿瘤富集区(TE)、免疫富集区(IE)、肿瘤/免疫界面(肿瘤界面=TX和免疫界面=IX)。
  • 使用NanoString GeoMx平台,采用来自免疫细胞谱、免疫治疗药物靶点、免疫激活状态、免疫细胞分型和泛肿瘤面板的52种蛋白标记进行DSP。

主要发现

  • 总体而言,基于DSP的标记表达显示高度瘤内异质性。
  • 缓解与PD-L1(不区分兴趣区域)、Ki-67(不区分兴趣区域、TE、IE和TX)、HLA-DR(TX)和HER2(TE)等标记相关。
  • 包含兴趣区域标记的弹性网模型验证集表现(AUC=0.827)优于忽略兴趣区域的模型(AUC=0.432)。
  • 包含DSP、肿瘤突变负荷和临床数据的模型表现(AUC=0.821)不优于仅DSP模型。

关键数值与推荐

  • 病理缓解定义为完全缓解ypT0N0和部分缓解<ypT2N0。
  • 缓解者定义为<ypT2,未缓解者定义为≥ypT2。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Platinum-based neoadjuvant chemotherapy (NAC) is standard for patients with muscle-invasive bladder cancer (MIBC). Pathologic response (complete: ypT0N0 and partial: <ypT2N0) to NAC is associated with improved survival with ypT0N0 achieved in 30-40% of cases. Strategies to increase response to NAC are needed. Incorporation of immune checkpoint inhibitors (ICIs) has demonstrated promise, and better spatial understanding of the tumor microenvironment may help predict NAC/ICI response. OBJECTIVE: Using the NanoString GeoMx platform, we performed proteomic digital spatial profiling (DSP) on transurethral resections of bladder tumors from 18 responders (<ypT2) and 18 nonresponders (≥ypT2) from two studies of NAC (gemcitabine and cisplatin) plus ICI (LCCC1520 [pembrolizumab] and BLASST-1 [nivolumab]). DESIGN, SETTING, AND PARTICIPANTS: Pretreatment tumor samples were stained by hematoxylin and eosin and immunofluorescence (panCK and CD45) to select four regions of interest (ROIs): tumor enriched (TE), immune enriched (IE), tumor/immune interface (tumor interface = TX and immune interface = IX). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: DSP was performed with 52 protein markers from immune cell profiling, immunotherapy drug target, immune activation status, immune cell typing, and pan-tumor panels. RESULTS AND LIMITATIONS: Protein marker expression patterns were analyzed to determine their association with pathologic response, incorporating or agnostic of their ROI designation (TE/IE/TX/IX). Overall, DSP-based marker expression showed high intratumoral heterogeneity; however, response was associated with markers including PD-L1 (ROI agnostic), Ki-67 (ROI agnostic, TE, IE, and TX), HLA-DR (TX), and HER2 (TE). An elastic net model of response with ROI-inclusive markers demonstrated better validation set performance (area under the curve [AUC] = 0.827) than an ROI-agnostic model (AUC = 0.432). A model including DSP, tumor mutational burden, and clinical data performed no better (AUC = 0.821) than the DSP-only model. CONCLUSIONS: Despite high intratumoral heterogeneity of DSP-based marker expression, we observed associations between pathologic response and specific DSP-based markers in a spatially dependent context. Further exploration of tumor region-specific biomarkers may help predict response to neoadjuvant chemoimmunotherapy in MIBC. PATIENT SUMMARY: In this study, we used the GeoMx platform to perform proteomic digital spatial profiling on transurethral resections of bladder tumors from 18 responders and 18 nonresponders from two studies of neoadjuvant chemotherapy (gemcitabine and cisplatin) plus immune checkpoint inhibitor therapy (LCCC1520 [pembrolizumab] and BLASST-1 [nivolumab]). We found that assessing protein marker expression in the context of tumor architecture improved response prediction.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Beckabir W, Wobker SE, Damrauer JS, et al. Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer. Eur Urol. 2023. PMID: 38092611. doi:10.1016/j.eururo.2023.11.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。